BR9916566A - Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo - Google Patents

Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo

Info

Publication number
BR9916566A
BR9916566A BR9916566-0A BR9916566A BR9916566A BR 9916566 A BR9916566 A BR 9916566A BR 9916566 A BR9916566 A BR 9916566A BR 9916566 A BR9916566 A BR 9916566A
Authority
BR
Brazil
Prior art keywords
cyclodextrin
ras
farnesyltransferase
complex
hydroxypropyl
Prior art date
Application number
BR9916566-0A
Other languages
English (en)
Inventor
Krishnaswamy S Raghavan
Timothy M Malloy
Sailesh A Varia
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR9916566A publication Critical patent/BR9916566A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"COMPLEXO DE INIBIDOR DE RAS-FARNESILTRANSFERASEE SULFOBUTILéTER-7-<225>-CICLODEXTRINA OU2-HIDROXIPROPIL-<225>CICLODEXTRINA E PROCESSO". éprovido um complexo inibidor de ras-farnesiltransferase formado deum inibidor de ras-farnesiltransferase ou um sal farmacologicamenteaceitável do mesmo, da fórmula (I), onde n é 0 ou 1; R~ 1~ éselecionado de Cl, Br, fenila, piridila ou ciano; R~ 2~ é aralquila;R~ 3~ é selecionado de alquila inferior, arila, arila substituída ouheterociclo; Z~ 1~ é selecionado de CO, S0~ 2~, CO~ 2~, SO~2~NR~ 5~ R~ 5~ é selecionado de hidrogênio, alquila inferior oualquila substituída; e sulfobutiléter-7-<225>-ciclodextrina ou2-hidroxipropil-<225>-ciclodextrina. O complexo possui,inesperadamente, solubilidade aquosa alta do inibidor deras-farnesiltransferase e é útil para sua liberação intravenosa aosseres humanos com câncer. Também é provido um processo paraformação do complexo. Os inibidores de ras-farnesiltransferase sãoúteis como agentes anti-tumor.
BR9916566-0A 1999-01-21 1999-12-21 Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo BR9916566A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11664799P 1999-01-21 1999-01-21
PCT/US1999/030424 WO2000042849A1 (en) 1999-01-21 1999-12-21 COMPLEX OF RAS-FARNESYLTRANSFERASE INHIBITOR AND SULFOBUTYLETHER-7-β-CYCLODEXTRIN OR 2-HYDROXYPROPYL-β-CYCLODEXTRIN AND METHOD

Publications (1)

Publication Number Publication Date
BR9916566A true BR9916566A (pt) 2001-11-13

Family

ID=22368422

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916566-0A BR9916566A (pt) 1999-01-21 1999-12-21 Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo

Country Status (33)

Country Link
US (1) US6218375B1 (pt)
EP (1) EP1143796A4 (pt)
JP (1) JP2002535253A (pt)
KR (1) KR100708360B1 (pt)
CN (1) CN1219517C (pt)
AR (1) AR022323A1 (pt)
AU (1) AU772204B2 (pt)
BG (1) BG105666A (pt)
BR (1) BR9916566A (pt)
CA (1) CA2359646C (pt)
CO (1) CO5160253A1 (pt)
CZ (1) CZ20012601A3 (pt)
EE (1) EE200100382A (pt)
GE (1) GEP20043214B (pt)
HK (1) HK1038865A1 (pt)
HU (1) HUP0105160A3 (pt)
ID (1) ID30139A (pt)
IL (1) IL144025A (pt)
LT (1) LT4893B (pt)
LV (1) LV12712B (pt)
MY (1) MY119700A (pt)
NO (1) NO20013585L (pt)
NZ (1) NZ511995A (pt)
PE (1) PE20001419A1 (pt)
PL (1) PL195280B1 (pt)
RU (1) RU2230062C2 (pt)
SK (1) SK9602001A3 (pt)
TR (1) TR200102109T2 (pt)
TW (1) TWI232752B (pt)
UA (1) UA67825C2 (pt)
UY (2) UY25986A1 (pt)
WO (1) WO2000042849A1 (pt)
ZA (1) ZA200104416B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
US6566347B1 (en) * 2001-08-22 2003-05-20 Duquesne University Of The Holy Ghost Controlled release pharmaceutical
AU2002359412A1 (en) * 2001-11-13 2003-05-26 Bristol-Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5- tetrahydro-1h-1,4-benzodiazepine compounds
KR100451485B1 (ko) 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
WO2003106628A2 (en) * 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20100204178A1 (en) * 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
EP1928464B1 (en) 2005-09-30 2014-05-14 Lundbeck Inc. Novel parenteral carbamazepine formulation
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
TW200806284A (en) * 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
KR20090087079A (ko) * 2006-11-21 2009-08-14 노파르티스 아게 벤조디아제핀 구조의 ｒｓｖ 억제제를 포함하는 안정한 비경구 제형
SG10201914059WA (en) 2008-10-22 2020-03-30 Array Biopharma Inc Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
NZ604498A (en) 2010-05-26 2014-10-31 Neurophyxia B V 2-iminobiotin formulations and uses thereof
WO2012034038A2 (en) * 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
US9309203B2 (en) * 2011-10-07 2016-04-12 Pisces Therapeutics, Llc Malignant and non-malignant disease treatment with Ras antagonists
CN105194685A (zh) * 2015-10-15 2015-12-30 重庆大学 磺胺脒的磺丁基醚-β-环糊精包合物及其粉针制剂
JP6975165B2 (ja) 2015-12-16 2021-12-01 ニューロフィシア・ベー・フェー 脳細胞傷害の処置における使用のための２−イミノビオチン
PE20181888A1 (es) 2016-04-04 2018-12-11 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
RU2745953C2 (ru) 2016-05-18 2021-04-05 Локсо Онколоджи, Инк. Способ получения (s)-n-(5-((r)-2-(2,5-дифторфенил)пирролидин-1-ил)-пиразоло[1,5-a]пиримидин-3-ил)-3-гидроксипирролидин-1-карбоксамида и его солей
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
US20210145816A1 (en) * 2019-11-15 2021-05-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
WO2023113479A1 (en) * 2021-12-15 2023-06-22 Sillajen, Inc. Pharmaceutical compositions comprising modified beta-cyclodextrins

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5630927A (en) * 1979-08-24 1981-03-28 Zeria Shinyaku Kogyo Kk Stabilization of guaiazulene and its derivative
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
JPH07165616A (ja) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc シクロデキストリンの複合組成物及び複合化法
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
JPH1067639A (ja) * 1996-08-26 1998-03-10 Shiseido Co Ltd ビタミンｅ−ビタミンｃリン酸ジエステル／シクロデキストリン包接物及び該包接物を配合した皮膚外用剤

Also Published As

Publication number Publication date
CO5160253A1 (es) 2002-05-30
WO2000042849A1 (en) 2000-07-27
IL144025A (en) 2004-05-12
TR200102109T2 (tr) 2001-12-21
CA2359646A1 (en) 2000-07-27
CN1333651A (zh) 2002-01-30
GEP20043214B (en) 2004-04-26
NO20013585L (no) 2001-09-04
AU2374000A (en) 2000-08-07
AR022323A1 (es) 2002-09-04
CZ20012601A3 (cs) 2002-05-15
HK1038865A1 (zh) 2002-04-04
HUP0105160A3 (en) 2003-01-28
KR20010101611A (ko) 2001-11-14
RU2230062C2 (ru) 2004-06-10
US6218375B1 (en) 2001-04-17
PL195280B1 (pl) 2007-08-31
JP2002535253A (ja) 2002-10-22
UY25987A1 (es) 2000-09-29
LV12712B (en) 2002-01-20
NO20013585D0 (no) 2001-07-20
NZ511995A (en) 2003-11-28
EP1143796A1 (en) 2001-10-17
ID30139A (id) 2001-11-08
BG105666A (en) 2002-04-30
CA2359646C (en) 2008-12-02
IL144025A0 (en) 2002-04-21
UY25986A1 (es) 2000-09-29
LT4893B (lt) 2002-02-25
HUP0105160A2 (hu) 2002-05-29
AU772204B2 (en) 2004-04-22
ZA200104416B (en) 2002-05-29
CN1219517C (zh) 2005-09-21
SK9602001A3 (en) 2002-06-04
TWI232752B (en) 2005-05-21
MY119700A (en) 2005-06-30
PE20001419A1 (es) 2001-02-21
EE200100382A (et) 2002-12-16
LT2001064A (en) 2001-10-25
EP1143796A4 (en) 2002-03-20
UA67825C2 (uk) 2004-07-15
KR100708360B1 (ko) 2007-04-17
PL366338A1 (en) 2005-01-24
LV12712A (lv) 2001-09-20

Similar Documents

Publication Publication Date Title
BR9916566A (pt) Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
BR0014136A (pt) Composto, uso do mesmo, métodos para a preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
FI953968A (fi) Antraniiliset happojohdannaiset
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
BR0115580A (pt) Derivados de 3-aroilindol e a utilizaçao dos mesmos como agonistas dos receptores cb2
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
BR9916781A (pt) 4-oxo-1,4-dihidro-3-quinolinacarboxamidas comoagentes antivirais
BR0014133A (pt) Uso de um composto, composto, métodos de preparação de um composto, e para inibir aurora 2 quinase em um animal de sangue quente, e, composição farmacêutica
CY1110284T1 (el) Παραγωγα της 2-αμινο-4-πυριδυλομεθυλο-θειαζολινης και η χρηση τους ως αναστολεις της επαγωγιμης συνθασης νο
BR0108816A (pt) Derivados de quinolina como antagonistas alfa-2
HUP0003942A2 (hu) Helyettesített 3,3-diamino-2-propén-nitrilek, előállításuk és alkalmazásuk
BR0014990A (pt) Derivados de tetrahidrotiopirano ranftalazinona como inibidores de pde4
DE69808099D1 (de) Substituierte 6-alkylphenanthridine
TR200001239T2 (tr) Tiyazolidinediyon türevlerini hazırlama prosesi.
DE60036558D1 (de) Phthalazinon-derivate als pde 4 hemmer
BR0112028A (pt) Inibidores de farnesil transferase
ATE348800T1 (de) 4&#39;-methansulfonylbiphenylderivate als hochselektive cyclooxygenase-2-inhibitoren
BR0016115A (pt) Derivados peptìdicos de acriloìla, processo para sua preparação e seu uso como agentes inibidores de tumor
AR045847A1 (es) Derivados del tiazol
BR0009856A (pt) Sìntese de 3-amino-3-aril propanoatos
ES2206296T3 (es) Derivados de tienopiranocarboxamida.
DE69932441D1 (de) Cyanoiminochinoxalin-derivate
ATE420855T1 (de) 2-substituierte vitamin-d-derivate
UY27464A1 (es) Compuestos de espiro-hidantoina utiles como agentes ant-inflamatorios.
BR0016418A (pt) Derivados piridina com atividade fungicida e processos de produção e utilização dos mesmos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: C07D 403/06, A61K 31/55, A61K 47/40, A81K 9/08

Ipc: A01N 43/00 (00000007), A61K 31/55 (2009.01)

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE ACORDO COM OS ARTIGOS 8O, 13 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.